Drugs that contain Brimonidine Tartrate

1. Drug name - ALPHAGAN P

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8858961 ALLERGAN Compositions containing alpha-2-adrenergic agonist components Sep, 2023

(11 months from now)

US8858961

(Pediatric)

ALLERGAN Compositions containing alpha-2-adrenergic agonist components Mar, 2024

(1 year, 5 months from now)

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.1% SOLUTION/DROPS;OPHTHALMIC Prescription

2. Drug name - LUMIFY

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8293742 BAUSCH AND LOMB INC Preferential vasoconstriction compositions and methods of use Jul, 2030

(7 years from now)

US9259425 BAUSCH AND LOMB INC Compositions and methods for eye whitening Jul, 2030

(7 years from now)

Treatment: Relieves redness of the eye due to minor eye irritations

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.025% SOLUTION/DROPS;OPHTHALMIC Over the counter

3. Drug name - MIRVASO

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8859551 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders May, 2024

(1 year, 7 months from now)

US8426410 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing inflammatory skin disorders May, 2025

(2 years from now)

US8410102 GALDERMA LABS LP Methods and compositions for treating or preventing erythema May, 2025

(2 years from now)

US8231885 GALDERMA LABS LP Compounds, formulations, and methods for ameliorating telangiectasis May, 2025

(2 years from now)

US7439241 GALDERMA LABS LP Compounds, formulations, and methods for treating or preventing rosacea Aug, 2025

(2 years from now)

US9861631 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema Mar, 2031

(8 years from now)

US9861632 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema Mar, 2031

(8 years from now)

US8513249 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema Mar, 2031

(8 years from now)

US8513247 GALDERMA LABS LP Methods and compositions for safe and effective treatment of erythema Mar, 2031

(8 years from now)

US8163725 GALDERMA LABS LP Gel compositions and methods of use Jun, 2031

(8 years from now)

US10201517 GALDERMA LABS LP Brimonidine gel compositions and methods of use Jun, 2031

(8 years from now)

US8053427 GALDERMA LABS LP Brimonidine gel composition Jun, 2031

(8 years from now)

Treatment: Topical treatment of facial erythema of rosacea

Dosage: GEL;TOPICAL

More Information on Dosage
Strength Dosage Availability
EQ 0.33% BASE GEL;TOPICAL Prescription

4. Drug name - QOLIANA

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US7265117 SANDOZ INC Topical brimonidine tartrate formulations that lack chlorine dioxide Aug, 2025

(2 years from now)

Treatment: NA

Dosage: SOLUTION/DROPS;OPHTHALMIC

More Information on Dosage
Strength Dosage Availability
0.15% SOLUTION/DROPS;OPHTHALMIC Prescription

availability in other generic markets.

Click on the highlighted region to filter.